AI Article Synopsis
- * Current practices around IgRT include various factors like dosing based on body weight, treatment duration, and the use of antibiotics and vaccines, but the true effectiveness varies among different disease groups.
- * There is a need for more research, including randomized controlled trials, to better understand the optimal use of IgRT and explore other therapies that could enhance patient outcomes and reduce healthcare costs.
Article Abstract
Acquired hypogammaglobulinemia or secondary immunodeficiency (SID) occurs commonly in hematological malignancies with increasing incidence and complexity in the era of modern therapies. Despite current practice of immunoglobulin replacement (IgRT) in SID, the evidence is lacking, especially for newer treatments. We discuss the current evidence for IgRT in various disease groups including issues, such as actual or ideal body weight (IBW)-based dosing, length of treatment, antibiotic prophylaxis, and vaccination. Incidence of SID with newer treatment is lacking. While there is a trend toward decreased respiratory infections and hospitalizations with IgRT, this is not consistent across all disease course or treatment groups. Dosing and indications for cessation of IgRT are also inadequately characterized. Further randomized controlled trials (RCTs) and observational studies are required to assess the optimal indications, timing, and duration of IgRT to improve the efficacy, safety, and cost-effectiveness. Assessment of alternative and adjunctive therapies, such as vaccination and antibiotic prophylaxis could also improve the outcomes and costs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2022.2131424 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of acquired immunodeficiency in a patient with b-cell chronic lymphocytic leukemia on the course of coronavirus disease (COVID-19): a case report.
Wiad Lek
December 2024
STATE INSTITUTION OF SCIENCE ≪CENTER OF INNOVATIVE HEALTHCARE TECHNOLOGIES≫ STATE ADMINISTRATIVE DEPARTMENT, KYIV, UKRAINE.
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder that affects the bone marrow, lymph nodes, and spleen, and is associated with certain complications. One of the complications of CLL is acquired immunodeficiency, leading to a predisposition for prolonged respiratory viral and bacterial infections. This publication presents a clinical case of a prolonged and severe course of COVID-19 in a patient with CLL, who was successfully treated with immunoglobulin replacement therapy.
View Article and Find Full Text PDFA Case of Hypercalcemia and Acute Kidney Injury Caused by Adrenal Insufficiency.
Cureus
November 2024
Department of Nephrology, Toho University Medical Center, Sakura Hospital, Sakura, JPN.
Hypercalcemia is a common electrolyte disturbance, most frequently caused by hyperparathyroidism or malignancy, though it can also arise from adrenal insufficiency, creating diagnostic challenges. We present a case of a 78-year-old male patient with stage 3b chronic kidney disease due to immunoglobulin A nephropathy who exhibited altered mental status following dehydration caused by a five-day episode of diarrhea. The patient presented with hypercalcemia and acute kidney injury.
View Article and Find Full Text PDFAdult-onset hypophosphatasia diagnosed after consecutive tooth loss during orthodontic treatment: a case report.
J Med Case Rep
December 2024
Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nakagami, Nishihara, Okinawa, 903-0215, Japan.
Background: Adult hypophosphatasia is an uncommon inherited disorder of mineral homeostasis affecting bone. It arises from mutations within the Alkaline Phosphatase, Biomineralization Associated (ALPL) gene, which encodes tissue-nonspecific alkaline phosphatase. Because of its low prevalence and non-specific clinical manifestations, underdiagnosis and misdiagnosis are frequent, particularly in Asian populations.
View Article and Find Full Text PDFReplacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibody.
BMC Infect Dis
December 2024
Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
Background: Virus neutralising antibodies in serum are considered key correlates of protection for vaccines and monoclonal antibodies against respiratory syncytial virus (RSV). RSM01 is a novel, highly-potent, half-life-extended and fully-human monoclonal antibody candidate targeting the RSV prefusion F protein. Currently in Phase 1 development, RSM01 is primarily being developed to potentially provide an effective and affordable RSV prevention strategy in low- and middle-income countries.
View Article and Find Full Text PDFSevere hypophosphataemia and hypocalcaemia following intravenous ferric derisomaltose and denosumab administration.
BMJ Case Rep
December 2024
Division of Endocrinology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Serum calcium and phosphorus levels are tightly regulated by the calciotropic hormone parathyroid hormone, fibroblast growth factor 23 and 1,25(OH) vitamin D. Commonly prescribed therapies for iron-deficiency anaemia (IDA) such as ferric carboxymaltose and ferric derisomaltose (FDM) have been shown to disrupt phosphorus homeostasis, resulting in hypophosphataemia. Similarly, denosumab use can result in hypocalcaemia due to the inhibition of osteoclastic maturation, activity and survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!